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theMitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous etiologies, including primary
(organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR,
which is principally caused by global or regional left ventricular remodeling and/or severe left atrial dilation. Diagnosis
and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons,
interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of trans-
catheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform
endpoint deﬁnitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a
collaboration between leading academic research organizations and physician-scientists specializing in MV disease from
the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart
failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisti-
cians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology,
prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial
design (Part 1) and endpoint deﬁnitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR.
The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness
evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of
new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement
initiatives. (J Am Coll Cardiol 2015;66:278–307) © 2015 by the American College of Cardiology Foundation.m the *Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York; yCardiovascular Research
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AB BR E V I A T I O N S
AND ACRONYM S
FDA = U.S. Food and Drug
Administration
GDMT = guideline-directed
medical therapy
LA = left atrial
LV = left ventricular
LVEF = left ventricular
ejection fraction
MR = mitral regurgitation
MV = mitral valve
MVARC = Mitral Valve
Academic Research Consortium
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiographyM itral regurgitation (MR) is the most preva-lent valvular disease in the United Statesand Europe, and along with aortic steno-
sis, is one of the most frequent valve disorders
referred for surgical correction (1–4). In contrast to
aortic stenosis, which is typically characterized by
severe and homogenous cusp calciﬁcation, MR is het-
erogeneous in etiology, mechanisms, and pathoanat-
omy. MR may develop either from primary pathology
involving any of the components of the mitral valve
(MV) apparatus (primary MR, also known as organic
MR, usually due to degenerative MV disease) or arise
secondarily to left ventricular (LV) dysfunction or oc-
casionally from left atrial (LA) dilation (secondary
MR, also known as functional MR) (1,2,5–7). Surgical
MV repair is the recommended approach for severe
primary MR, with a recently accepted role for trans-
catheter repair for patients who are at very high or pro-
hibitive surgical risk (1,2,8). Conversely, secondary
MR is typically treated with medications and (if indi-
cated) biventricular pacing for heart failure, and coro-
nary revascularization when appropriate, with the
utility of MV surgery and transcatheter devices repre-
senting active areas of investigation (8). Few random-
ized trials, however, have been performed to evaluate
the safety and efﬁcacy of MV therapies. The introduc-
tion of transcatheter MV devices and the performance
of a randomized trial comparing 1 such device to
MV surgery (8) have exposed the complexities re-
quired to properly evaluate MR therapies, speciﬁcally
regarding the appropriate study population and con-
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280clinical trials and registries investigating transcatheter
device therapies to treat MR, which may also be
applied to surgical and other approaches. Three in-
person meetings were held in 2012 to 2014 in which
stakeholders and experts in MV disease and thera-
peutics from theUnited States and Europe convened to
comprehensively review the principles and elements
required to successfully investigate and evaluate the
relative risks versus beneﬁts of MV therapies. As listed
in the Online Appendix, these multidisciplinary gath-
erings included specialists in general cardiology and
valve disorders, heart failure, cardiac surgery, inter-
ventional cardiology, imaging, statistics and epide-
miology, and clinical trials. Representatives from the
FDA Center for Devices and Radiological Health
participated in an advisory role.MVARCwas funded by
multiple industry sponsors who did not participate in
either the sessions or document preparation, but were
provided a copy of the report before submission. No
fees or honoraria were provided to the writing group or
participants.
The present document that resulted from this effort
is meant to summarize the current state of knowledge
and consensus expert opinion for MR therapies and
is organized in 2 parts: recommendations for clinical
trial design principles (Part 1), and consensus
endpoint deﬁnitions (Part 2). We acknowledge that
the ﬁeld of MV therapeutics is highly dynamic and
evolving, and we anticipate regular revisions to these
recommendations. Finally, we have concentrated our
current effort on therapies for primary and secondary
MR; however, many of the principles in this document
may also be applied to other MV conditions, including
treatment of mitral stenosis, degenerated mitral
bioprostheses, and failed surgical valvuloplasty.
OVERVIEW: INVESTIGATIVE AND
REGULATORY PERSPECTIVES
Clinical trials that are intended to support device
regulatory approval or expansion of indications must
have clearly documented objectives and be per-
formed in a highly rigorous manner. In Europe, the CE
mark process requires demonstration that the device
is safe and functions both medically and technically
as the manufacturer intends. Effectiveness is usually
investigated after CE mark approval, and post-
marketing surveillance is an integral part of ongoing
clinical evaluation. Either randomized trials or well-
performed registries may support CE mark approval.
For example, both the MitraClip edge-to-edge device
(Abbott Vascular, Santa Clara, California) and the
Carillon coronary sinus annuloplasty device (Cardiac
Dimensions, Kirkland, Washington) received a CEmark to treat MR on the basis of registry data
demonstrating safety.
For U.S. FDA regulatory approval, high-risk class III
devices must demonstrate “reasonable assurance” of
both safety and effectiveness in a well-deﬁned pop-
ulation for its intended use. Pivotal evaluations of
breakthrough technologies such as transcatheter
mitral repair systems or percutaneous implantable
valves will, in most cases, necessitate randomized
controlled trial designs wherein the new device is
compared with the currently established standard of
care therapy, unless approval for a very limited pa-
tient cohort is desired for which randomization is not
feasible. For example, the MitraClip was approved in
the U.S. to treat symptomatic patients with severe
primary MR at prohibitive surgical risk on the basis of
high-quality registry data.
For U.S. approval trials, depending on the com-
parator group, either a superiority or noninferiority
design for the primary endpoint may be appropriate.
Although superiority in either safety and/or effec-
tiveness is typically preferred for FDA regulatory
approval, a new device may demonstrate non-
inferiority for both and still be approvable as an
alternative therapy to the existing standard of care,
depending on the beneﬁt-risk balance. In studies
addressing an unmet clinical need for a severe dis-
ease in which the available therapeutic alternatives
are suboptimal, the beneﬁt-risk proﬁle of an investi-
gational device may also be favorable even if effec-
tiveness is somewhat less than that of the comparator
if treatment with the investigational device shows
evidence of substantial safety beneﬁts (and is more
effective than a putative placebo) (20). As knowledge
accumulates and technology matures, noninferiority
designs (e.g., comparing a new design to a previously
approved transcatheter device) and even non-
randomized comparisons to performance goals or
objective performance criteria may become reason-
able to evaluate device iterations and to expand the
indications for use (label expansion) of existing
approved devices.
Primary effectiveness should be evaluated with a
clinically relevant endpoint, either a single event
type (e.g., hospitalization for heart failure) or a com-
posite measure (e.g., death or hospitalization for
heart failure). Additional support for effectiveness
can be obtained through the use of validated in-
struments demonstrating improved quality-of-life,
improvement in symptom status (e.g., New York
Heart Association [NYHA] functional classiﬁcation),
and improved exercise performance. Although at the
present time these measures are not usually suff-
icient for principal FDA regulatory device approval,
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281increasing attention is being paid to patient-centered
beneﬁt-risk metrics in device approval decisions.
Evidence of meaningful MR reduction by the device
that is sustained over time is important to demon-
strate, and improvement in ventricular volumes and
function during follow-up are additional supportive
secondary effectiveness endpoints that should be
assessed. Safety assessments may include both short-
and long-term procedural and device-related com-
plications, and a primary safety endpoint (separate
from the primary effectiveness endpoint) should be
pre-speciﬁed (see Primary and Secondary Endpoints).
Finally, the duration of follow-up must be sufﬁcient
to ensure adequate device durability, relevant to the
population being studied and comparable to alterna-
tive therapies, if available. Late device failures may
occur after the primary endpoint of pre-market
studies, necessitating robust post-market surveil-
lance to monitor long-term device performance after
regulatory approval.
Identifying the intended population for use (e.g.,
primary vs. secondary MR, high vs. low surgical risk,
and so on) may importantly affect decisions on
comparator therapies (e.g., medical, surgical, or other
transcatheter devices; see Control Group Therapies).
As a general principle, because the pathophysiology,
prognosis, control groups, and response to therapies
for primary and secondary MR vary greatly, these 2
conditions should be studied in separate in-
vestigations unless randomization is stratiﬁed and
each cohort is individually powered for both safety
and effectiveness. As a corollary, inclusion and
exclusion criteria must be carefully selected to deﬁne
the population of use (see Inclusion and Exclusion
Criteria). Because transcatheter devices for MR are
likely to be evaluated over a range of disease severity
and comorbidities, detailed anatomic and clinical
characterization is required, in addition to key sur-
rogates such as MR quantiﬁcation and structural
cardiac evaluation using imaging techniques (see
Assessment of Mitral Regurgitation: Role of Nonin-
vasive Imaging).
Determining operative risk is central to deﬁning
the population for intended use of a new device as
well as selecting the appropriate comparator arm.
Current scoring systems such as the Society of
Thoracic Surgeons (STS) and EuroSCORE II indexes
(21–23) may not by themselves be sufﬁcient to deﬁne
risk or operability in all patients. Assessment of pa-
tient operability (which may deﬁne clinical trial
eligibility) should be determined by a local multidis-
ciplinary heart team after comprehensive patient
evaluation (including risk score assessment). For MR
studies, the heart team should usually include valveand heart failure specialists, MV surgeons, interven-
tional cardiologists experienced in transcatheter MV
procedures, imaging experts, and potentially others
depending on the speciﬁc population and device
being studied (see also the subsection Role of the
Heart Team).
Several trials may now be cited wherein the use of
a sham control helped to demonstrate a lack of device
efﬁcacy, contrary to the results of prior unblinded
investigations (24–26). Use of sham controls (if
possible) are thus desirable and, in most cases, are
ethically justiﬁable (see also discussion on sham
controls in Control Group Therapies). When a sham
control is not feasible, additional efforts should be
considered to blind the patient and participants
involved in data collection to the extent possible
(e.g., the use of patient headphones to mask device
allocation during the procedure; not recording
randomization allocation in the chart; and using
separate research coordinators and physicians for
device implantation and follow-up). Patient-related
outcomes, such as quality-of-life, are considered
more robust in studies that can be blinded. For
pivotal device trials, the use of independent core
laboratories and event adjudication and data safety
and monitoring committees are mandatory to ensure
patient safety, reduce reporting bias, and enhance
credibility, accuracy, and interpretability of study
ﬁndings, especially when patient and physician
blinding is not possible.
For both randomized trials and registry studies of
MR therapies, written informed consent must be ob-
tained from all patients unless waivers are provided
with speciﬁc ethical oversight. Within the framework
of a randomized trial, study-eligible patients who
decline randomization should ideally be followed in a
separate registry to provide additional insights into
potential study selection bias and the natural history
of the control population. If exploratory comparison
with randomized trial arms is contemplated, the
statistical methodology must be pre-speciﬁed and
justiﬁed (e.g., propensity scoring analysis with
appropriate covariates, and so on).
Finally, although randomized trials with primary
clinical endpoints are strongly recommended, given
the logistical, time and cost constraints, MVARC
acknowledges that many investigations of MV thera-
peutics will collect observational or registry data only
(preferably compared with either a concurrent or
historical control group), or if randomized, will not be
powered for clinical endpoints. Potential efﬁcacy
endpoints for these studies may include reduction in
MR grade, improvement in LV pressures and chamber
dimensions, improved quality of life, and enhanced
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Endpoints). However, currently none of these end-
points have been sufﬁciently linked to a major clinical
outcome such as death or heart failure hospitalization
to be considered a true surrogate, especially as pro-
cedural risks must be taken into account when
considering the beneﬁt-risk proﬁle of a novel therapy.
As such, these studies should be considered hypoth-
esis generating with regard to clinical utility. None-
theless, such investigations are valuable in their
own right, and they provide important supportive
data when considering the utility of a new device
or approach. Further studies are warranted to
strengthen the association between these nonclinical
endpoints and clinical outcomes such that, in the
future, they might serve as primary endpoints in FDA
regulatory trials.
PRIMARY VERSUS SECONDARY MR:
SIMILARITIES, DIFFERENCES, AND
IMPLICATIONS FOR TRIAL DESIGN
CLASSIFICATION OF MR AND IMPLICATIONS FOR
MV THERAPIES. Accurate diagnosis of the underlying
MV anatomy and pathophysiology is essential to un-
derstand the etiology, mechanism, lesion localiza-
tion, and severity of MR; to establish its prognosis;
and to design appropriate trials of MR therapies. The
MV complex is a dynamic structure including the
annulus, the anterior and posterior leaﬂets and
commissures, different level chordae tendineae, the
papillary muscles, the underlying LV myocardium,
and the LA. Pathological changes in any of the com-
ponents of the MV can lead to MR, and often lesions
are present in more than 1 structural component of
the valve. Assessment of MR involves comprehensive
evaluation of its etiology and mechanism (the lesion
or deformation resulting in valve dysfunction),
including the dysfunction type (leaﬂet motion ab-
normality) (27–29). Of note, annular dilation is almost
universally present in patients with severe MR,
regardless of other structural abnormalities, although
it typically develops late. One exception is MR arising
secondary to LA dilation (often in the setting of atrial
ﬁbrillation), in which annular dilation may be the
principal mechanism of MR (5,6). Comprehensive
characterization of the underlying etiology and MV
lesion(s) in each patient is especially critical in the
new device era, as many transcatheter devices
mechanistically target only a single component of the
MV or a single mechanism of MR.
The mechanism of MR may be described by Car-
pentier’s classiﬁcation of leaﬂet motion: type I:
normal leaﬂet motion (e.g., annular dilation, leaﬂetperforation, or clefts), type II: excessive leaﬂet mo-
tion (e.g., chordal elongation or rupture), and type III:
restricted leaﬂet motion (Figure 1) (30). Type III
dysfunction is further subclassiﬁed according to
restricted leaﬂet motion predominantly in diastole
but also in systole (type IIIa [e.g., rheumatic disease])
versus only in systole (type IIIb [e.g., ischemic or
nonischemic LV remodeling with leaﬂet tethering due
to local or diffuse ventricular dilation]). Carpentier’s
segmental leaﬂet anatomy classiﬁcation is a useful
construct when describing MV disease and planning
and performing an intervention (30).
PRIMARY VERSUS SECONDARY MR. The ﬁrst and
most important distinction that must be drawn is to
classify the underlying etiology as either predomi-
nantly: 1) primary MR (also commonly known as
organic MR), which is due to underlying degenera-
tive/structural MV pathology; or 2) secondary MR
(also known as functional MR), which is principally
caused by global or regional LV remodeling and/or
severe LA dilation, in which case the MV structures
are usually normal or exhibit only secondary late
ﬁbrosis and/or annular dilation. As discussed in the
following text, this distinction currently serves as the
central basis for selecting standard of care therapies,
which will dictate the choice of control group in
randomized trials.
Primary MR usually implies Carpentier type II
dysfunction, but may be type I in endocarditis and
type IIIa in cases of rheumatic origin. Primary MV
disease is the most common form of MR referred for
surgical correction and covers a large spectrum of
lesions, ranging from abnormalities in an isolated
scallop to multisegment (or generalized) prolapse,
and from thin/nonredundant leaﬂets to thickened
leaﬂets with excess tissue (Barlow’s disease) (28).
Prolapse location, the presence of valvular/annular
calciﬁcation, and the severity of annular dilation may
affect the feasibility and choice of surgical and
transcatheter mitral repair techniques (31).
Secondary MR usually implies a Carpentier type
IIIb dysfunction, although type I dysfunction with
isolated annular dilation may occur secondary to LA
dilation. Secondary MR most commonly develops
despite a structurally normal MV due to mitral leaﬂet
tethering secondary to ventricular deformation/
remodeling, annular dilation/dysfunction, and in-
sufﬁcient LV-generated closing forces. Assessing
global LV function and dilation (diameters, volumes,
sphericity, mass) and local remodeling (displacement
of papillary muscles) as well as MV deformation
(coaptation depth, tenting area, and tenting volume
in 3 dimensions) is of paramount importance in
FIGURE 1 Mitral Valve Anatomy and Carpentier Classiﬁcation of Mitral Regurgitation
Type I
Normal leaflet
motion 
Type II
Increased leaflet
motion
Type IIIa
Restricted leaflet
motion
(systole and diastole)
Type IIIb
Restricted leaflet
motion
(systole) 
(Top) The middle scallop of the posterior leaﬂet is designated as P2 and the adjacent lateral and medial segments are P1 and P3. The opposing
segments of the anterior leaﬂet are designated as A1, A2, and A3. AC and PC represent the anterolateral and posteromedial commissures.
(Bottom) Leaﬂet dysfunction (Carpentier type I, type II, type III) is classiﬁed on the basis of motion of the free margin of the leaﬂet in relation to
the annular plane.
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283evaluating the potential for reparability and results of
treatment (32,33). Tethering may be limited to an
isolated leaﬂet segment on the basis of “localized”
ventricular remodeling or be present along the entire
MV closure line in end-stage and diffuse ventricular
remodeling. The degree of secondary MR may vary
greatly depending on loading conditions (more so
than in primary MR).
Secondary type IIIb MR can further be sub-
classiﬁed as arising from underlying ischemic heart
disease (usually prior myocardial infarction) versus
nonischemic dilated cardiomyopathy (whether idio-
pathic or due to speciﬁc causes such as hyper-
tension). The mitral jet is typically eccentric or
commissural in the setting of ischemic disease and
posterior infarction, resulting in posterior leaﬂet
tethering with medial commissural gap, and is central
in most cases when the LV is globally dilated due to
anterior infarction or nonischemic cardiomyopathy,resulting in more symmetric displacement of both
papillary muscles.
It is particularly important to differentiate and
separate populations of patients with primary versus
secondary MR in clinical trial design (Table 1), as the
comorbidities, prognosis, and therapeutic approaches
in these patients vary greatly. Most patients with
primary MR due to degenerative MV disease achieve
long-term event-free survival similar to an age-
matched population after MV surgery, provided MR
correction is achieved through valve repair surgery
rather than valve replacement, and before signiﬁcant
deterioration in LV geometry or function (1). In
contrast, patients with secondary MR have varying
degrees of myocardial remodeling and dilation, and
usually have signiﬁcant LV dysfunction. Most pa-
tients with secondary MR are treated with heart
failure therapies (guideline-directed medical therapy
[GDMT]  cardiac resynchronization therapy [CRT]
TABLE 1 Implications of the Etiology of Mitral Regurgitation
Primary Mitral Regurgitation Secondary Mitral Regurgitation
Prognosis Primarily dependent on the
severity of mitral regurgitation
and secondarily on left and
right ventricular function and
pulmonary pressures
Primarily dependent on the
degree of underlying left
ventricular dysfunction and
secondarily on the severity
of mitral regurgitation
Principal management
strategy (standard
of care)
Mitral valve surgery when severe
(repair preferred to
replacement); MitraClip may
be considered in patients at
prohibitive surgical risk with
appropriate anatomy
GDMT for heart failure  cardiac
resynchronization therapy 
coronary revascularization
when indicated; mitral valve
surgery (repair or
replacement) is not common
clinical practice but may be
considered in selected cases
GDMT ¼ guideline-directed medical therapy.
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284when appropriate) as well as coronary revasculariza-
tion if substantial ischemia is present. For patients
failing those initial treatments, advanced therapies
including LV assist devices and heart transplantation
may be considered. In patients with severe LV
dysfunction, the long-term prognosis may be dictated
more by the extent of ventricular dysfunction and
remodeling than the severity of secondary MR. There
is currently little evidence that survival or the natural
history of the underlying myocardial disease are
affected by mitral intervention in patients with sec-
ondary MR, although reduction or correction of MR
may provide symptomatic relief (34–36).
ASSESSMENT OF MR:
ROLE OF NONINVASIVE IMAGING
ECHOCARDIOGRAPHIC EVALUATION OF MR. Echo-
cardiography is fundamental in evaluating the etiol-
ogy, mechanisms, and severity of MR, and its effect
on cardiac structures and function. In addition,
serial echocardiography is essential to demonstrate
the effects of medical therapy, devices, and surgical
MV repair and replacement over time. Routine
2-dimensional (2D) transthoracic echocardiography
(TTE) differentiates whether MR is due to primary
valve degeneration or is secondary to LV dysfunction
or LA dilation. For primary MR, 2D TTE discriminates
the speciﬁc pathological changes in the MV complex.
In the presence of mixed pathologies, classiﬁcation
can be more difﬁcult (e.g., secondary MR with notable
annular calciﬁcation or leaﬂet thickening), although
usually a predominant etiology can be assigned.
Speciﬁc anatomical measurements are also useful
in assessment of secondary MR (Figure 2), including
leaﬂet length, leaﬂet angles (particularly the pos-
terolateral angle, indicating posterior leaﬂet teth-
ering), coaptation distance (apical displacement ofthe coaptation point), coaptation length, and tenting
area. Asymmetric tenting indicates posterior leaﬂet
restriction, whereas symmetric tenting indicates
bileaﬂet restriction. Measurements of global LV
remodeling include LV diameters/volumes and the
sphericity index. Measurements of local LV remod-
eling include apical displacement of the postero-
medial papillary muscle, second order chords, and
the interpapillary muscle distance (Figure 2) (29,37).
Finally, echocardiographic measures of annular di-
mensions (anterior-posterior diameter >35 mm or the
ratio of the anterior-posterior diameter to mid-
diastolic anterior MV leaﬂet length >1.3) due to LV
dysfunction, dilation, or dyssynchrony have prog-
nostic signiﬁcance (37,38).
QUANTIFICATION OF MR. Three echocardiographic
grades of MR severity are generally recognized:
mild, moderate, and severe. Whereas this 3-group
classiﬁcation is preferred, a 4-group quantitative
scale is sometimes used as well, wherein 1þ ¼ mild
MR, 2þ ¼moderate MR, 3þ ¼moderate-to-severe MR,
and 4þ ¼ severe MR. Because each echocardiographic
measurement has speciﬁc limitations and lack of
precision, an integrated approach incorporating
multiple variables should be used to assess MR
severity, with somewhat different criteria for primary
and secondary MR (Tables 2 and 3) (29,39). These
include qualitative ﬁndings (MV morphology, color
ﬂow, and continuous wave signals of the MR jet),
semiquantitative measures (vena contracta width,
pulmonary vein ﬂow, mitral inﬂow), and quantitative
measures (regurgitant volume [RVol] and effective
regurgitant oriﬁce area [EROA]), as well as supportive
ﬁndings (enlarged LV and/or LA, increased pulmo-
nary artery pressure [PAP]) (Figures 3 and 4). MR
severity should be evaluated by 2D TTE in the non-
sedated, nonanesthetized patient, although 2D and
3-dimensional (3D) transesophageal echocardiog-
raphy (TEE) may improve assessment, particularly in
secondary MR (Figure 5). Moreover, for consideration
of patient eligibility for a trial evaluating treatment of
chronic MR, the echocardiographic severity of MR
must be evaluated during a period of clinical stability.
If the patient presents with decompensated LV fail-
ure, the degree of MR should not be assessed until at
least 30 days after the patient has stabilized on a
maximal medical regimen.
Color ﬂow imaging is not solely used for grading
MR severity. Localization, duration, timing, and
direction of the regurgitant jet into the LA may be
useful to evaluate MR, both at baseline and during
follow-up after device or surgical intervention.
When feasible, the vena contracta width and the
FIGURE 2 Echocardiographic Measurements in Secondary Mitral Regurgitation
(A) Global left ventricular (LV) remodeling (LV diameter, LV volume, sphericity index [SI] [SI ¼ L/1, where L is the major axis and 1 is the minor
axis]). (B) Local LV remodeling (1, apical displacement of the posteromedial papillary muscle; 2, second order cords; 3, interpapillary muscle
distance). (C) Mitral valve deformation (1, systolic tenting area [TA]; 2, coaptation distance [CD]; 3, posterolateral angle [PLA]). The single-
headed arrows are pointing to structures. The double-headed arrows represent length measurements. Reproduced with permission
from Lancellotti et al. (29). PLL ¼ posterior leaﬂet length.
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285ﬂow convergence method (proximal isovelocity
surface area [PISA], which permits assessment of
RVol and EROA) are strongly recommended. Inherent
limitations of the PISA method should be appreciated,
however, including reduced accuracy with eccentric
or multiple jets (especially common in secondary MR
or after transcatheter MV repair with certain devices),
changes in PISA radius throughout systole, and difﬁ-
culty in precisely locating the regurgitant oriﬁce.
In addition, the assumption that the proximal
ﬂow convergence is hemispheric (vs. ellipsoidal orirregularly shaped, as in secondary MR [40], leading
to underestimation of MR severity) and that it
occurs over a ﬂat surface (requiring angle correc-
tion in some cases, including post-MitraClip) are
important limitations. By permitting direct planim-
etry of the vena contracta (as well as multiple jets),
3D-TEE may provide a more accurate assessment of
MR severity, especially in secondary MR (41,42).
However, both 2D and 3D color ﬂow Doppler may
overestimate the oriﬁce area due to aliasing and
blooming artifacts. Despite these limitations, PISA is a
TABLE 2 Grading the Severity of Primary Mitral Regurgitation by Echocardiography
MR Severity*
Mild Moderate Severe
Qualitative
MV morphology Mildly abnormal leaﬂets (e.g., mild
rheumatic thickening, limited prolapse)
Moderately abnormal leaﬂets (e.g.,
moderate thickening or prolapse)
Severe valve lesions (e.g., ﬂail leaﬂet,
ruptured papillary muscle, severe
retraction, large perforation)
Color ﬂow MR jet Small LA penetration or not holosystolic Moderate LA penetration or large
penetration and late systolic
Deep LA penetration and holosystolic jet
Flow convergence zone† Not visible, transient or small Intermediate in size and duration Large throughout systole
CW signal MR jet Faint/partial/parabolic Dense but partial or parabolic and
light density
Holosystolic and dense or triangular
Semiquantitative
Vena contracta width, mm <3 Intermediate ‡7 (>8 for biplane)‡
Pulmonary vein ﬂow Systolic dominance Systolic blunting§ May be normal with low LA pressure.
Systolic ﬂow reversal
Mitral inﬂowk A-wave dominant Variable E-wave dominant (>1.5 cm/s)
TVI mitral/TVI aortic ratio <1.0 1.0–1.4 >1.4
Quantitative
EROA, mm2 <20 20–29; 30–39¶ $40
Regurgitant volume, ml <30 30–44; 45–59¶ $60
LV and LA size Usually normal Usually normal or mild dilation Usually dilated#
PA systolic pressure, mm Hg Usually normal Usually normal May be normal; >50 at rest without
other cause
General considerations: All measurements have limitations, and an integrated approach must be used that weighs the strength of each echocardiographic measurement. All signs and measures should be
interpreted in an individualized manner that accounts for body size, sex, and all other patient characteristics. Finally, there may be uncertainty in classifying mild versus moderate and moderate versus severe
MR. Further differentiation may be obtained with additional testing (e.g., exercise echocardiography, cardiac magnetic resonance imaging, right and left heart catheterization) if clinically indicated or needed
for clinical trial classiﬁcation. Bolded qualitative and semi-quantitative signs are considered speciﬁc for their MR grade. *Mild MR ¼ 1þ; moderate MR ¼ 2þ; moderate-severe MR ¼ 3þ; and severe MR ¼ 4þ.
†With Nyquist limit >50 to 60 cm/s. ‡For average between apical 2- and 4-chamber views. §Signs are nonspeciﬁc and are inﬂuenced by many other factors (LV diastolic function, atrial ﬁbrillation, LA
pressure). kSigns are nonspeciﬁc, are most valid in patients >50 years of age, and are inﬂuenced by other causes of elevated LA pressure. ¶The 2 ranges indicate mild/moderate and moderate/severe MR
respectively. EROA 30 to 39 mm2 or RVol 45 to 59 ml may be consistent with severe MR in individuals of small body size, particularly women. #LV and LA can be within the “normal” range for patients with
acute severe MR or with chronic severe MR who have small body size, particularly women, or with small LV size preceding the occurrence of MR. Modiﬁed with permission from Lancellotti et al. (29) and
Zoghbi et al. (39).
CW ¼ continuous wave; EROA ¼ effective regurgitant oriﬁce area; LA ¼ left atrium; LV ¼ left ventricular; MR ¼mitral regurgitation; MV ¼mitral valve; PA ¼ pulmonary artery; TVI ¼ time velocity integral.
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286practical method that correlates well with the
severity of MR and prognosis.
Importantly, systolic regurgitant ﬂow lasts only as
long as mitral leaﬂet malcoaptation persists; there-
fore, EROA and RVol are dynamic. For example, in
MV prolapse, the EROA appears or increases in mid-
to-late systole, whereas in secondary MR, it de-
creases in mid systole. EROA is usually holosystolic
in severe MR. In the current valve guidelines from
both the United States and Europe (1,2), an EROA $40
mm2 (RVol $60 ml) indicates severe primary MR,
whereas an EROA $20 mm2 (RVol $30 ml) indicates
severe secondary MR. These different thresholds for
severe MR due to primary and secondary MV
dysfunction have been largely derived from outcome
studies demonstrating the prognostic effect of vary-
ing degrees of quantitatively measured MR in the 2
conditions (29,43). In both cases, however, the
regurgitant fraction is $50%. Of note, however, a
regurgitant fraction $50% can be produced by
different values of EROA and RVol, depending on LV
volumes and ejection fraction, which can vary widely
in secondary MR. Therefore, deﬁning severe MRrequires careful integration of all echocardiographic
data (Tables 2 and 3) (44).
Exercise echocardiography can demonstrate the
dynamic nature of MR (mild-moderate MR increasing
to severe MR during exercise) and exercise-induced
pulmonary hypertension (45). In asymptomatic pa-
tients with primary MR and borderline normal values
of LV function and size, worsening of MR (with
increasing systolic PAP) and lack of contractile reserve
during exercise echocardiography are associated with
worse outcomes (46). In patients with secondary MR
and chronic LV dysfunction, worsening MR with in-
crease in EROA by$13 mm2 with exercise is associated
with a poor prognosis (47,48). Increasing LV dyssyn-
chrony with increased MR can also occur during ex-
ercise and may improve after CRT. Improved regional
wall motion during (low-level) exercise indicates re-
sidual viability, whereas worsening regional wall
motion indicates ischemia. Although exercise echo-
cardiography is increasingly used, the accurate
assessment of MR severity during peak exercise re-
mains technically challenging. Pharmacological stress
alone is incapable of comprehensively evaluating
TABLE 3 Grading the Severity of Secondary Mitral Regurgitation by Echocardiography
MR Severity*
Mild Moderate Severe
Qualitative
MV morphology Normal leaﬂets with mild tenting Leaﬂets with moderate tenting Severe tenting and movement restriction
with leaﬂet coaptation reduced to
leaﬂet tips or locally absent
Color ﬂow MR jet Small Moderate penetration of the
aliasing jet
Large jet with profound LA penetration
of the aliasing jet
Flow convergence zone† None or small Intermediate Large
CW signal MR jet Low density or incomplete duration May be dense or holosystolic Dense and holosystolic, low velocity
and triangular
Semiquantitative
Vena contracta width, mm <3 Intermediate $7 (>8 for biplane)‡
Pulmonary vein ﬂow§ Systolic dominance§ (may be absent with
restrictive ﬁlling or atrial ﬁbrillation)
Systolic blunting is nonspeciﬁc§ Systolic ﬂow reversal§
Mitral inﬂow§ A-wave dominant§k Variable§ E-wave dominance (nonspeciﬁc§)
Quantitative
EROA, mm2¶ Not established Not established $20
Regurgitant volume, ml¶ Not established Not established $30
LV and LA size and systolic PAP# Variable Variable Variable
General considerations: All measurements have limitations, and an integrated approach must be used that weighs the strength of each echocardiographic measurement. All signs and measures
should be interpreted in an individualized manner that accounts for body size, sex, and all other patient characteristics. These recommendations are for holosystolic MR. The values of EROA
and RVol associated with severe MR (regurgitant fraction >50%) should be consistent with LV end-diastolic volume, LVEF, and LV forward stroke volume calculated by other methods. The
values presented here are rough guides (44). Functional MR is dynamic, and EROA changes during systole (may be limited to early and late systole) and over time (depending on loading
conditions). In such circumstances, single-frame PISA or 3-dimensional measurements may overestimate MR severity. There may be uncertainty in classifying mild versus moderate and
moderate versus severe MR. Further differentiation may be obtained with additional testing (e.g., exercise echocardiography, cardiac magnetic resonance imaging, right and left heart
catheterization) if clinically indicated or needed for clinical trial classiﬁcation. *Mild MR ¼ 1þ; moderate MR ¼ 2þ; moderate-severe MR ¼ 3þ; and severe MR ¼ 4þ. †At a Nyquist limit of 50 to
60 cm/s. ‡For average between apical 2- and 4-chamber views. §Pulmonary venous ﬂow and mitral inﬂow are indirect signs of MR and are inﬂuenced by many other factors such as LV systolic
and diastolic function, LA size and pressure, atrial arrhythmias, and the presence of mitral inﬂow obstruction. Pulmonary venous ﬂow reversal, which is speciﬁc to severe primary MR, is rarely
observed in severe functional MR. kUsually in patients>50 years of age. ¶EROA and regurgitant volume by PISA may be substantially underestimated in secondary MR if the regurgitant oriﬁce
is elliptical or has multiple jets, as is often the case. Several but not all studies have shown an adverse prognosis with EROA $20 mm2 or regurgitant volume$30 ml in secondary MR. It is not
clear what the cutoff values for mild vs moderate MR should be, in part because of absence of a clear gold standard. 3-dimensional imaging of EROA should be considered in such patients,
although it tends to overestimate actual EROA (42). #In secondary MR, LV and LA size and PAP may be increased by the underlying LV systolic and diastolic dysfunction and, therefore, may be
increased in all grades of MR.
PAP ¼ pulmonary artery pressure; PISA ¼ proximal isovelocity surface area; other abbreviations as in Table 2.
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287dynamic changes in MR. Further studies are war-
ranted to evaluate the role of exercise echocardiog-
raphy in the risk stratiﬁcation of patients with MR.
ASSESSING THE CONSEQUENCES OF MR. LV dia-
meters are derived from M-mode echocardi-
ography or 2D imaging. LV end-systolic diameter >40
to 45 mm and left ventricular ejection fraction
(LVEF) <60% are indicators of LV systolic dysfunc-
tion/dilation in the patient with severe MR. The 2D-
based biplane Simpson’s method is recommended for
estimation of LV volumes and LVEF; 3D assessment of
LV function is generally more accurate than 2D im-
aging. The LA dilates in chronic volume and pressure
overload; the biplane area-length method using
apical 2- and 4-chamber views is recommended for
assessing LA size. An LA volume index >60 ml/m2
predicts a poor prognosis in primary MR. However,
LA dilation is more nonspeciﬁc than LV dilation, as LA
enlargement can also occur in the setting of atrial
ﬁbrillation or secondary to an increase in LV end-
diastolic pressure, whether due to LV diastolic or
systolic dysfunction. A systolic PAP (obtained as thesum of the transtricuspid pressure gradient and the
estimated right atrial pressure) >50 mm Hg at rest or
>60 mm Hg with exercise is strongly associated
with adverse outcomes in primary MR. Elevated
PAP results in right ventricular pressure overload,
which may induce right ventricular failure, and
echocardiographic signs include right ventricular
hypertrophy, dilation, impaired function, and in-
creased tricuspid regurgitation (peak jet velocity >3
m/s) (49). Tricuspid annular dilation ($40 mm or >21
mm/m2) contributes to tricuspid regurgitation after
MV surgery, in which case tricuspid annuloplasty may
be considered concomitant with MV surgery (29).
ECHOCARDIOGRAPHIC ELIGIBILITY CRITERIA FOR
SURGICAL AND TRANSCATHETER MV REPAIR OR
REPLACEMENT. Surgical and transcatheter MV repair
or replacement is generally reserved for severe MR
(3þ to 4þ) (1,2,50). Echocardiographic eligibility
criteria must also carefully consider the likelihood of
procedural success for surgery and the experimental
transcatheter device. For example, in primary MR,
FIGURE 3 Echocardiographic Measurements to Quantify Severe Mitral Regurgitation
A 72-year-old patient with ischemic cardiomyopathy and severe secondary mitral regurgitation visualized with color Doppler showing a jet regurgitant area occupying the
entire left atrial area (A). On a zoomed view of the mitral leaﬂet coaptation (B), color Doppler acquisition permits measurement of the vena contracta width (7 mm,
double arrowhead). Continuous wave Doppler along the regurgitant jet shows the dense, holosystolic and triangular shape of the spectral signal (C, arrow). Using pulsed
wave Doppler, the early diastolic transmitral velocity (E-wave) is prominent (1.25 m/s) (D), and the pulmonary venous ﬂow shows systolic reversal of the ﬂow (E, arrow).
A ¼ late diastolic velocity; D ¼ diastolic pulmonary vein ﬂow; E ¼ early diastolic velocity.
Stone et al. J A C C V O L . 6 6 , N O . 3 , 2 0 1 5
MVARC Part 1: Clinical Trial Design Principles J U L Y 2 1 , 2 0 1 5 : 2 7 8 – 3 0 7
288successful surgical MV repair may be compromised in
the setting of multiple complex regurgitant jets,
extensive leaﬂet or valve calciﬁcation, and/or
when $3 scallops (particularly affecting the anterior
leaﬂet) are involved (51,52). In secondary MR, the risk
of unsuccessful surgical repair or MR recurrence is
increased with the presence of severely altered ge-
ometry of the MV apparatus, severe global LV
remodeling, and/or extensive basal LV scar or aneu-
rysm (Table 4) (29).
Given their varying mechanisms of action, the
echocardiographic determinants of successful trans-
catheter repair of MR are likely to be device speciﬁc.
For example, the MitraClip reduces MR by grasping
and approximating the anterior and posterior mitral
leaﬂets (8). Echocardiography is indispensable indetermining the complexity of the anatomic lesion,
and whether the amount of leaﬂet tissue and coap-
tation depth and length are sufﬁcient to afford leaﬂet
grasping and approximation by the MitraClip (Table 5)
(52). The precise echocardiographic features for pro-
cedural success or failure for transcatheter devices
that reduce MR by other mechanisms, such as direct
or indirect annuloplasty and MV replacement, are
notably different and unique to each device.
IMAGING DURING AND AFTER MV REPAIR AND
REPLACEMENT PROCEDURES. Echocardiography is
vital for assessing the acute and late results of both
surgical and transcatheter mitral interventions. As
regards surgery, 2D TEE (complemented by 3D TEE
when available) is performed acutely in the operating
theater after surgical MV repair to exclude more than
FIGURE 4 Quantiﬁcation of Mitral Regurgitation Using the
Proximal Isovelocity Surface Area Method
EROA = 2πr2 × Va / Vmax
R Vol = EROA × VTI
To calculate the effective regurgitant oriﬁce area (EROA), the
radius (r) of the hemispheric convergence ﬂow is measured on a
zoomed apical 4-chamber view. To better visualize the largest
ﬂow convergence, the color scale baseline (Nyquist) is reduced
to velocities around 35 cm/s. The Nyquist limit is considered the
velocity of aliasing (Va) and is introduced in the formula. From
the continuous wave Doppler of the regurgitant jet, the peak
velocity (Vmax) is measured and the velocity time integral (VTI)
is calculated. Regurgitant volume (RVol) is then calculated from
the EROA and the VTI.
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289mild residual valvular MR (e.g., vena contracta width
>3 mm). Adequate leaﬂet coaptation (length $8 mm)
should be veriﬁed. Leakage due to anatomic/tech-
nical problems or ring dehiscence and MV stenosis
(MV area <1.5 cm2, mean transmitral gradient $5
mm Hg) should be excluded (53). Systolic anterior
motion of the MV and injury to the left circumﬂexFIGURE 5 Evaluation of Secondary Mitral Regurgitation With 3-Dim
(A) Full volume of a dilated left ventricle and tethered mitral leaﬂets. T
of coaptation between the central scallops (B, arrows). With 3-dimensio
from the LA “en face” view of the mitral valve (C, arrow). Post-process
ﬂattening of the mitral annulus and tethering of the mitral leaﬂets (bluartery (expressed as wall motion abnormalities in the
basal and mid inferolateral LV segments) due to the
close proximity of sutures needed for annuloplasty
ring ﬁxation or compression by the ring itself should
also be excluded (53).
LV function may worsen after surgical MV re-
pair and should thus be evaluated in the immediate
post-operative period. Historically, this has been
attributed to the increase in LV afterload due to
reduction in MR. However, after MitraClip repair,
cardiac output generally increases, LV ﬁlling pres-
sures tend to normalize, and signiﬁcant LV dysfunc-
tion is uncommon, even in patients with severe
baseline LV dysfunction (54). This suggests that the
LV dysfunction observed in some patients after MV
surgery may be attributable to myocardial oxidative
stress, systemic inﬂammation and free radical injury
from cardiopulmonary bypass, cardiac arrest, and
cardioplegia, rather than to increased afterload due to
the reduction in MR (55).
In addition to assessing the acute results of trans-
catheter device repair or replacement of MR, echo-
cardiography is essential to guide most transcatheter
MV procedures. For example, 2D and 3D TEE are
used to guide each step of MitraClip implantation
(49), complementing ﬂuoroscopy. Immediate post-
procedural echocardiographic evaluation includes
assessment of residual MR, potential MV stenosis,
and exclusion of complications (e.g., pericardial
effusion/tamponade, thrombus formation on clips,
[partial] clip detachment, and entrapment of chordae
by the clip).
Depending on the device, echocardiographic
assessment of MR severity after transcatheter MV
procedures may pose unique challenges. For
example, MR quantiﬁcation with color ﬂow Doppler isensional Transesophageal Echocardiography
he left atrial (LA) “en face” view of the mitral valve shows normal mitral leaﬂets with lack
nal transesophageal echocardiography color Doppler data, the regurgitant ﬂow is observed
ing software permits reconstruction of a 3-dimensional model (D) of the mitral valve showing
e). A ¼ anterior; AL ¼ anterolateral; Ao ¼ aorta; P ¼ posterior; PM ¼ posteromedial.
TABLE 5 Relationshi
Suitability for the Mit
Ideal Valv
Mitral regurgitation ori
portion of the valve
functional etiology)
Lack of calciﬁcation in
Mitral valve area >4 cm
Length of posterior lea
Nonrheumatic or endoc
Flail width <15 mm, ﬂa
Sufﬁcient leaﬂet tissue
coaptation: coaptat
coaptation length >
Adapted with permission f
3D ¼ 3-dimensional; TEE
TABLE 4 Unfavorable Transthoracic Echocardiographic
Characteristics for Surgical Mitral Valve Repair in
Secondary Mitral Regurgitation
1. Mitral valve remodeling
 Coaptation distance $10 mm
 Tenting area >2.5–3.0 cm2
 Complex regurgitant jets
 Posterolateral angle >45
2. Local left ventricular remodeling
 Interpapillary muscle distance >20 mm
 Posterior papillary-ﬁbrosa distance >40 mm
 Lateral wall motion abnormality
3. Global left ventricular remodeling
 End-diastolic diameter >65 mm
 End-systolic diameter >51 mm (end-systolic volume >140 ml)
 Systolic sphericity index >0.7
Adapted with permission from Lancellotti et al. (29).
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290complex in the setting of a double MV oriﬁce after the
MitraClip, and artifacts from the clip(s) hamper
quantiﬁcation. Pulse wave Doppler of the pulmonary
veins is useful to corroborate a reduction in MR.
Speciﬁcally, pulmonary vein ﬂow reversal should be
eliminated, and there is often a conversion from the
pulmonary vein ﬂow from a “D” dominant pattern
(consistent with an elevated LA pressure) to an “S”
dominant pattern, reﬂecting a drop in LA pressure
secondary to MR reduction. MV stenosis should be
excluded, as evidenced by mean transmitral valve
gradient <5 mm Hg and MV area $1.5 cm2. Assess-
ment of paravalvular leak is particularly important in
patients undergoing transcatheter and surgical MV
replacement (56,57).
For both surgical and transcatheter MV procedures,
evaluation of the immediate post-repair/replacement
results should be performed when the patient’s bloodp Between the Morphological Characteristics of the Mitral Valve and
raClip Procedure
e Morphology Unsuitable Valve Morphology
ginating from the mid
(degenerative or
Perforated mitral leaﬂets or clefts, lack of
primary and secondary chordal support
the grasping area Severe calciﬁcation in the grasping area
2 Hemodynamically relevant mitral stenosis
ﬂet $10 mm Length of posterior leaﬂet <7 mm
arditic valve disease Rheumatic valve disease (restriction in
systole and diastole) or endocarditic
valve disease
il gap <10 mm 3D TEE gap between leaﬂets >2 mm
for mechanical
ion depth <11 mm,
2 mm
rom Wunderlich et al. (49).
¼ transesophageal echocardiography.pressure is at least equal to the basal state (and after
the effects of anesthesia have worn off). Compre-
hensive follow-up TTE is typically recommended at
1 month, at 6 months, and then annually to serially
assess MR severity, chamber volumes and pressures,
and structural and functional device performance
(including the detection of speciﬁc device-related
technical failure issues and complications as dis-
cussed in part 2 of this document).
For clinical trials using serial echocardiographic
imaging to assess device performance, study-speciﬁc
site training and certiﬁcation in imaging quality
before enrollment are recommended, and should be
conducted in collaboration with an independent
echocardiographic core laboratory.
ROLE OF NOVEL IMAGING TECHNOLOGIES: 3D TEE,
INTRACARDIAC ECHOCARDIOGRAPHY, CMR, AND
MDCT. In MV disease, 2D TTE and 2D TEE are the
standard imaging modalities. Three-dimensional
TEE has substantially improved visualization of MV
anatomy and function, and the spatial relation of the
valve with its surrounding structures (Figure 6). Su-
perior diagnostic accuracy for MV prolapse (with
anterior leaﬂet and commissural involvement)
(Figure 6), perforations, and clefts has been reported
(53). Three-dimensional TEE improves MR quantiﬁ-
cation (speciﬁcally in eccentric or multiple jets), im-
proves vena contracta width assessment, and permits
direct measurement of the anatomic EROA (58). Post-
processing precisely delineates the mitral annulus,
leaﬂet lengths, leaﬂet angles, coaptation length, and
tenting area (Figure 7) (59). Three-dimensional TEE
may also be useful to guide transcatheter MV repair
procedures, such as the MitraClip (Figure 8).
Conversely, intracardiac echocardiography is rarely
used to guide MitraClip procedures, as acquisition of
the different views needed during the procedure can
be challenging, but may be useful for other trans-
catheter MV applications (60).
Advanced imaging techniques, including cardiac
magnetic resonance (CMR) and multidetector row
computed tomography (MDCT), can provide comple-
mentary information in patients with MR. Both CMR
and MDCT permit assessment of LA and LV volumes,
function, sphericity, and scar tissue. Given its high
spatial resolution, MDCT can accurately delineate MV
anatomy (Figure 9) (59,61) and is uniquely useful in
demonstrating the size and course of the coronary
sinus in relation to the mitral annulus and circumﬂex
coronary artery (Figure 10), which is an important
consideration for some transcatheter MV devices (62).
CMR may have particular value in the precise quan-
tiﬁcation of MR (Figure 11) (63); however, like all other
FIGURE 6 Assessment of Mitral Valve Morphology With 3-Dimensional Transesophageal Echocardiography in
Primary Mitral Regurgitation
(A) LA “en face” view of the normal mitral valve with anterior and posterior mitral leaﬂets divided in 3 scallops (A1-P1: lateral; A2-P2: central;
A3-P3: medial). (B) Prolapse of the anterior mitral leaﬂet with ﬂail of the A2 scallop (arrow). (C) Isolated prolapse of the P2 scallop. (D and E)
Examples of prolapse of the anterior and posterior commissures (arrows), respectively. The aortic valve (Ao) and the left atrial appendage
(LAA) are landmarks for orientation of the LA “en face” view of the mitral valve. Abbreviations as in Figure 5.
FIGURE 7 Measurement of Mitral Leaﬂets and Annulus Dimensions From 3-Dimensional Transesophageal Echocardiography
Accurate measurements of the mitral leaﬂets and annulus can be obtained by creating 3-dimensional (3D) reconstructions of the mitral valve
from 3D transesophageal echocardiography data. The multiplanar reformation planes are aligned across the mitral annulus (A) providing
LV outﬂow tract, bicommissural, and cross-sectional views of the mitral valve. (B) By tracing the leaﬂets and determining the mitral annulus
landmarks, the 3D models are created, and the post-processing software provides semiautomatic measurements of the mitral leaﬂets and
annulus. Reproduced with permission from Shanks et al. (59). LA ¼ left atrium; LV ¼ left ventricle; other abbreviations as in Figure 5.
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FIGURE 8 Transesophageal Echocardiogram Evaluation of MitraClip Implantation in a Patient With Severe Secondary Mitral Regurgitation
From the midesophageal 4-chamber (A) and bicommissural (B) views, the vena contracta width of the central regurgitant jet can be measured. The 3D LA “en face”
view shows lack of coaptation between the anterior and posterior mitral leaﬂets at the central level (C, arrows). With 3D color Doppler data, the convergence ﬂow can be
observed along the coaptation line from the LV view (D, arrows). Three MitraClip devices were successfully implanted with signiﬁcant reduction of MR as observed
from the color Doppler biplane views of the MV (E). On 3D transesophageal echocardiogram full volume of the mitral valve, the LA “en face” view shows a double oriﬁce
mitral valve after MitraClip implantation (F). The clips were positioned at the central and anterolateral levels (arrow) leading to a large oriﬁce at the posteromedial
level and a small anterolateral oriﬁce (F, asterisks). (G) The color Doppler 3D “en face” view of the mitral valve with 2 residual mild regurgitant jets. Abbreviations as
in Figures 5 and 7.
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292imaging modalities, the accuracy of CMR in assessing
MR severity is reduced in the setting of atrial ﬁbril-
lation. In the future it is likely that CMR and MDCT
will be increasingly used for pre-procedural assess-
ment and planning of both surgical and transcatheter
MR repair and replacement procedures, and post-
intervention surveillance.
CONTROL GROUP THERAPIES
Selection of the appropriate control group is essential
to interpreting the beneﬁt-risk proﬁle of a new de-
vice. For randomized MR clinical device trials, 3
control groups may be considered: 1) GDMT alone
(with or without a sham control) when GDMT is
standard of care; 2) GDMT plus surgical therapy when
surgical therapy is standard of care; and 3) GDMT plus
an active comparator device if an alternative device is
available and is considered a standard of care.
Ensuring the use of appropriate GDMT is a re-
quirement for all patients enrolled in randomized
controlled trials and registries. It is the basis uponwhich the safety and incremental efﬁcacy of proce-
dural therapies may be judged. GDMT in symptom-
atic patients with severe MR includes treatments for
heart failure (for all patients with secondary MR due
to LV dysfunction, and for those with primary MR
with symptoms of heart failure or volume overload
(class D), especially those in whom surgery is not
performed or will be delayed) (1). GDMT includes not
only the use of speciﬁc recommended therapies, but
also titration of those therapies to recommended
target doses, as tolerated. Optimal GDMT use before
study enrollment minimizes the likelihood of major
changes in medication dosing during the course of a
trial, deﬁned for each drug class as an increase in
dose by $100% or decrease in dose by $50% from
baseline. Thus, patients should meet pre-deﬁned
GDMT dosing stability criteria before randomization,
as the initiation, discontinuation, or titration of
therapies after randomization (in either the treat-
ment of control groups) may otherwise seriously
confound interpretation of the study results.
Although it may not be possible to always prevent
FIGURE 9 Multidetector Row Computed Tomography for Assessment of Mitral Valve Geometry in Secondary Mitral Regurgitation
From the reconstructed short-axis view of the mitral valve, orthogonal planes can be placed across the anterolateral, central, and postero-
medial levels of the MV leading to the left ventricular outﬂow tract view at each level. The angles (Aa and Pa) and tenting (MVTht) of the mitral
leaﬂets can be measured at the anterolateral (A1-P1), central (A2-P2), and posteromedial (A3-P3). Reproduced with permission from Delgado
et al. (61). AC ¼ anterior commissure; Ao ¼ aorta; PC ¼ posterior commissure; RA ¼ right atrium; RVOT ¼ right ventricular outﬂow tract.
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293major changes in drug dosing (e.g. after improvement
in hemodynamics with effective MR therapy), in
general such changes should be minimized to isolate
the effect of the randomized treatment, unless they
are pre-speciﬁed and considered as part of the
treatment arm strategy (including, for instance, a
prospective approach to reduction of heart failure
medications).
Achieving and maintaining maximally tolerated
guideline recommended doses of beta-blockers,
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers, and mineralocorticoid re-
ceptor antagonists is especially important before
enrollment in secondary MR trials, as reduction in LV
dimensions and LV remodeling with effective medical
therapy in heart failure may substantially reduce
MR in individual patients, obviating the need for
advanced or experimental therapies. MR severity
and appropriateness for study eligibility should bereassessed at least 30 days (and preferably 90 days)
after any major change in GDMT.
Compliance with optimal GDMT in individual pa-
tients is often challenging and should be documented
at baseline and throughout the course of the study.
Before enrollment, the adequacy of GDMT in indi-
vidual patients (including drug class, dose, and pa-
tient compliance) should be veriﬁed by a central
eligibility committee to reduce bias associated with
subjects changing their behavior under observation
post-enrollment (Hawthorne type effect) (see also
Role of the Central Eligibility Committee). Into-
lerance to a drug or drug class or limitation in drug
dosing should be on the basis of objective clinical
criteria, according to the known adverse effects of
speciﬁc agents, and must be well-documented in the
medical chart and study case report form. Examples
include symptomatic hypotension with angiotensin-
converting enzyme inhibitors, hyperkalemia with
FIGURE 10 Multidetector Row Computed Tomography for
Assessment of the Size and Course of the Coronary Sinus in
Relationship to the Mitral Annulus and
Circumﬂex Coronary Artery
The example shows a large coronary sinus (CS) that courses
relatively superior to the mitral annulus in its proximal part and
crosses above the left circumﬂex coronary artery (Cx) in its distal
part (arrow).
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294mineralocorticoid receptor antagonists, and symp-
tomatic bradycardia with beta-blockers.
In addition to GDMT for heart failure, appro-
priate patients should also be treated with biven-
tricular pacing (CRT) and coronary revascularization
when substantial ischemia is present, according
to contemporary clinical practice guidelines, such
as those from the American College of Cardiology
Foundation/American Heart Association (1,50) and
the European Society of Cardiology/European Asso-
ciation for Cardio-Thoracic Surgery (2). CRT is indi-
cated (Class I) in patients with NYHA functional class
II to IV symptoms on GDMT with LVEF #35%, sinus
rhythm, a left bundle branch block pattern, and QRS
duration $150 ms (50). In such patients, CRT may
substantially decrease LV dimensions and reduce
MR in as many as 50% of patients (64–67). CRT may
also be considered (Class IIa) for selected patients
with a left bundle branch block pattern and QRS
duration <150 ms, and for those with a non–left
bundle branch block and QRS duration $150 ms
(Class IIa) (50). Surgical or percutaneous coronaryrevascularization in patients with substantial ischemia
may also, on occasion, reduce secondary MR and
should be performed in appropriate patients before
study enrollment (68,69). After CRT or coronary
revascularization, at least 30 days (and preferably 90
days) should pass, after which TTE or other relevant
imaging tests are repeated to assess MR severity and
appropriateness for study eligibility. Similar to
optimal GDMT use, whether CRT and/or coronary
revascularization are indicated and utilized should be
veriﬁed by the central eligibility committee before
study enrollment.
APPROPRIATE SCENARIOS FOR GDMT ALONE (WITH OR
WITHOUT A SHAM) AS THE CONTROL GROUP. GDMT
should be used alone as the comparator (control)
group when a surgical comparator is either not indi-
cated (i.e., is not standard of care) or is contra-
indicated due to high surgical risk, and no other
active comparator exists. Examples of this scenario
are seen in recent studies of TAVR for critical aortic
stenosis in extreme surgical risk patients (70) and
from a single arm registry of the MitraClip for primary
MR in prohibitive surgical risk patients (35). Another
example comes from the ongoing COAPT (Cardio-
vascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients with
Functional Mitral Regurgitation) trial of the MitraClip
for severe secondary MR in chronic heart failure pa-
tients (NCT01626079). Although some practice vari-
ability exists in this setting, GDMT (rather than MV
surgery) is considered the default therapy for most
patients with secondary MR, a conclusion supported
by both the current United States and European
guidelines (1,2). Thus, the control group in COAPT is
GDMT alone for patients in whom MV surgery is not
considered appropriate after comprehensive individ-
ualized evaluation by the local heart team (see also
the subsection Role of the Heart Team).
For patients randomized to the control group, a
sham control procedure, in which an invasive pro-
cedure is performed but the device is not implanted,
should be strongly considered when feasible.
Although the implanting physician cannot be blinded,
use of a sham control minimizes bias by facilitating
blinding of study patients as well as the clinicians and
investigators responsible for follow-up study assess-
ments. There are now several notable examples in
which favorable results from unblinded studies were
not supported by sham-controlled randomized trials,
including studies of percutaneous myocardial laser
revascularization for refractory angina (24), closure of
patent foramen ovale for migraines (25), and renal
denervation for hypertension (26). The major limita-
tions to the use of sham controls are: 1) ethical
FIGURE 11 Quantiﬁcation of Mitral Regurgitant Volume With 3-Dimensional Velocity Encoded Cardiac Magnetic Resonance
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From a 3-dimensional (3D) volume of the heart, the volume of interest is positioned at the atrioventricular level including the systolic excursion of the mitral annulus.
The volume is then reformatted in 2-chamber (2CH) and 4-chamber (4CH) views, and the transmitral ﬂow is quantiﬁed from the 3D velocity vector ﬁeld. During diastole,
the mitral inﬂow is acquired, and in systole, the regurgitant ﬂow can be identiﬁed. Through-plane motion correction is performed from the longitudinal velocity
measured in the lateral wall (green regions of interest). The regurgitant volume is obtained by calculating the Riemann sum of the backward ﬂow during systole in
the ﬂow graph. Reproduced with permission from Ajmone Marsan et al. (63).
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beneﬁt); and 2) difﬁculties in maintaining the blind.
The nature of the sham control will vary according to
the control procedure, and should be selected to
maximize the goal of maintaining the blind while
minimizing patient risk. For example, for procedures
in which the experimental procedure requires a trans-
septal puncture, the sham control procedure may
include femoral venous access and right heart cath-
eterization. Conversely, a sham control may not be
possible for an invasive procedure such as apical
insertion of a transcatheter mitral valve. Use of a
sham control may be less critical if the primary
endpoint of the trial is mortality, although even in
this case bias in an open-label study may differen-
tially affect medical compliance and crossover to
other therapies.
APPROPRIATE SCENARIOS FOR SURGICAL THERAPY AS
THE CONTROL GROUP. Surgical therapy (on a back-
ground of GDMT) should be considered as the controlgroup when surgical therapy is the standard of care
and patients are acceptable surgical candidates. This
is the situation for most patients with primary MR
who are not considered to be at very high operative
risk.
APPROPRIATE SCENARIOS FOR AN ACTIVE COMPARATOR
DEVICE AS THE CONTROL GROUP. An active comparator
device (on a background of GDMT) may be considered
as the control group when another approved device is
indicated for use in the population being studied. For
example, in the United States, for symptomatic pa-
tients with severe primary MR at prohibitive surgical
risk (deﬁned by the FDA as an STS score for 30-day
mortality of $8 [replacement calculator] or $6
[repair calculator] or the presence of 1 or more high-
risk features that, in the opinion of an experienced
MV surgeon, otherwise precludes surgery), the
MitraClip might currently serve as an active compar-
ator for either a randomized trial or single-arm reg-
istry, assuming appropriate MV anatomy. Speciﬁc
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appear in Table 6.
INCLUSION AND EXCLUSION CRITERIA
Table 7 details numerous considerations for inclusion
and exclusion criteria for investigational MR trials
that may be used as a framework. Although each trial
will need to tailor these criteria to the speciﬁc device
and patient population being studied, general prin-
ciples may be applied when selecting patients with
primary and secondary MR for enrollment in MV
trials.
RISK SCORES AND SURGICAL CANDIDACY. A major
decision point that must be reached early is whether
the patient is an acceptable surgical candidate.
Several risk scores are in widespread use to determine
short-term morbidity and mortality after cardiac
surgery that account for patient comorbidities and
ventricular function. General recommendations for
the use of risk scores and assessments of comorbid-
ities for patients undergoing TAVR have been
recently reviewed in the Valve Academic Research
Consortium-2 consensus document (17). MVARC rec-
ommends adoption of a similar approach to integra-
tion of risk scores and comorbidities for studies of
devices treating MR, in particular with regard to the
classiﬁcation of surgical risk related both to prognosis
and selection of the appropriate control group.
The STS score and EuroSCORE II are currently most
commonly recommended for this purpose (22,23).
The STS score provides separate scores for surgicalTABLE 6 Recommended Control Groups for Transcatheter
Device Trials in Patients With Mitral Regurgitation
Control Group
Primary mitral regurgitation
Acceptable surgical risk Mitral valve surgery (repair preferable
to replacement)  GDMT* (if heart
failure or left ventricular
dysfunction present)
High surgical risk† GDMT* or MitraClip
Secondary mitral regurgitation
Acceptable surgical risk GDMT*‡
High surgical risk† GDMT*
*Maximally tolerated doses of recommended medications for heart failure.
Appropriate patients also should have been treated with CRT and/or coronary
revascularization before study enrollment. †The deﬁnition of high surgical risk may
vary according to national standards of care. In the United States, per current U.S.
Food and Drug Administration guidelines, patients with primary mitral regurgita-
tion should be determined to be at “prohibitive surgical risk” for GDMT or
approved transcatheter devices to be considered as an acceptable control group in
regulatory trials. ‡In patients for whom the local standard of care for secondary
mitral regurgitation is not surgical mitral valve repair or replacement. Mitral valve
repair or replacement might also be a suitable control group for selected patients
in whom the local standard of care for secondary mitral regurgitation is mitral
valve surgery, depending on the experimental device characteristics (e.g., for
studies of transcatheter mitral valve replacement).
GDMT ¼ guideline-directed medical therapy.MV repair and MV replacement, and is recommended
for use in clinical trials. Conventionally, very high or
”prohibitive” surgical risk is deﬁned by an estimated
surgical 30-day mortality of $8% using the STS
replacement calculator or $6% using the STS repair
calculator; however, such scores, although having
good discrimination, have relatively poor calibration
and therefore limited accuracy in identifying extreme
risk patients (71). Moreover, few patients with pro-
hibitive risk for surgical treatment of MR were
included in the cohorts used to develop and validate
the STS and EuroSCORE II.
Of note, the STS and EuroSCORE II were developed
from outcomes in patients who actually underwent
surgery, whereas transcatheter devices for MR may
warrant evaluation in patients too sick for surgery,
who are not represented by these scoring systems.
Thus, similar to the Valve Academic Research
Consortium-2 recommendations, other variables that
are not captured in these scores should also be
considered when deciding whether a patient is at
excessive risk for surgery, including frailty, major
organ system compromise (e.g., cirrhosis), and
procedure-speciﬁc impediments (Table 8) (1). Addi-
tional factors that may preclude surgery include se-
vere mitral annular calciﬁcation, the presence of a
hostile chest (e.g., prior mediastinal radiation or chest
malformation), patent left internal mammary artery
bypass graft crossing the midline, prior tracheotomy,
and severe pulmonary hypertension with or without
right ventricular dysfunction.
A speciﬁc issue unique to MV therapeutics refers to
use of the STS repair versus replacement calculator to
determine surgical risk. This is an important consid-
eration, as the replacement calculator yields greater
predicted perioperative mortality. For studies of pri-
mary MR in nonprohibitive risk patients in whom
surgical MV repair is generally the standard of care, it
is appropriate to use the STS mitral repair calculator
to determine surgical risk. Conversely, for studies of
secondary MR, MV surgery is not generally consid-
ered the standard of care, and GDMT (CRT as
appropriate) is the mainstay therapy. In secondary
MR patients who are operated on, MV repair has not
been proven superior to MV replacement (34); most
patients will be of at least moderate surgical risk
given their underlying cardiomyopathy; and most
high-risk patients with secondary MR who are oper-
ated on currently receive MV replacement rather than
repair (at least in the United States) (72). It is, there-
fore, reasonable to use the STS mitral replacement
calculator to determine surgical risk for studies of
devices for secondary MR. Additional considerations
regarding the choice of the appropriate surgical risk
TABLE 7 Recommended Major Inclusion and Exclusion Criteria for Transcatheter Device Trials in Patients with Mitral Regurgitation
Inclusion Criteria
Age $18 yrs
Degree of MR: Severe (or 3þ and 4þ)*
LVEF >20% (primary MR) or $20% to #60% (secondary MR)†‡
Symptom status: NYHA functional class II to IVa§
Treatment and compliance with optimal guideline-directed medical therapy for heart failure for at least 30 days (preferably 90 days)
MR mechanism/anatomy: Appropriate to the design speciﬁcations of each device
Surgical risk: Speciﬁc STS risk score criteria and/or the presence of high-risk features or comorbidities, depending on the speciﬁc trial aims
Completion of required functional tests (e.g., 6-min walk) and/or quality-of-life assessments
Exclusion Criteria
Life expectancy <1 yr due to noncardiac conditions
NYHA functional class IVb or ACC/AHA stage D heart failure
Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support
UNOS status 1 heart transplantation or prior orthotopic heart transplantation
Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other
than dilated cardiomyopathy of either ischemic or nonischemic etiology
Fixed pulmonary artery systolic pressure >70 mm Hgk
Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
Mitral valve anatomy which may preclude proper device treatment
Mitral valve area <4.0 cm2 (if new device therapy may further decrease the mitral oriﬁce area)
Any prior mitral valve surgery or transcatheter mitral valve procedure
Stroke or transient ischemic event within 30 days before randomization
Modiﬁed Rankin Scale $4 disability
TAVR within 1 month before randomization
Severe symptomatic carotid stenosis (>70% by ultrasound).
Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
Absence of CRT with Class I indication criteria for biventricular pacing
Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-deﬁbrillator within 1 month before randomization
Untreated clinically signiﬁcant coronary artery disease requiring revascularization
Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
Tricuspid valve disease requiring surgery or severe tricuspid regurgitation
Aortic valve disease requiring surgery
Need for any cardiovascular surgery (other than for MV disease)
Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
Active endocarditis
Active infections requiring current antibiotic therapy
Subjects in whom transesophageal echocardiography is contraindicated or high risk
Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical
therapy) and follow-up visits
Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment
*Ideally as assessed by an independent echocardiographic core laboratory. Different quantitative criteria may apply for primary and secondary MR. See Assessment of Mitral
regurgitation: Role of Noninvasive Imaging. †As a starting point for consideration. The upper limit of LVEF should be selected to ensure inclusion of patients with true secondary
MR due to LV dysfunction. By unloading the LV, severe MR increases the LVEF, and LVEF #60% is consistent with LV dysfunction; however, lowering the upper limit of the
LVEF range (e.g., to #50%) may be considered to increase speciﬁcity. Similarly, the lower level of LVEF should be selected to ensure exclusion of patients who might not be
capable of beneﬁtting from MR reduction. An acute increase in afterload by reducing or eliminating MR may also (rarely) result in hemodynamic compromise in the early post-
intervention period. In general, a lower limit LVEF of 20% is recommended. Lower and upper limits for LV dimensions should also be considered on the basis of the speciﬁc
device being tested. ‡In the case of secondary MR, if patients with both ischemic and nonischemic dilated cardiomyopathy are enrolled, randomization should be stratiﬁed by
this variable. §As a starting point for consideration. Patients should be symptomatic, and most patients should be ambulatory (able to complete a 6-min walk test). Dedicated
trials, however, may be designed for asymptomatic or end-stage patients. kAssessed by echocardiography or right heart catheterization, unless active vasodilator therapy in the
catheterization laboratory is able to reduce the pulmonary vascular resistance to <3 Wood Units or between 3 and 4.5 Wood Units, with v-wave less than twice the mean of the
pulmonary capillary wedge pressure.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ cardiac resynchronization therapy deﬁbrillator;
LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve; UNOS ¼ United Network
for Organ Sharing.
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297calculator should take into account the device char-
acteristics, access, mode of action, and the procedure
the device is intended to replace.
ROLE OF THE HEART TEAM. The standard of care for
any individual patient, including assessment of sur-
gical candidacy, appropriate use of GDMT, and po-
tential clinical trial eligibility, should be determined
by a multidisciplinary heart team consisting of local
experts experienced in the care of patients with MV
disease (1,17). At a minimum, the heart team should
include a heart failure/valve cardiologist, an inter-
ventional cardiologist skilled in the relevant accessand device implantation procedures, an MV cardiac
surgeon, and an imaging specialist. Depending on
the speciﬁc trial, additional members of the heart
team might also include an electrophysiologist, a
stroke neurologist, an anesthesiologist, and a geria-
trician. Other health care professionals, such as
pharmacists and behavioral specialists, may also
provide needed expertise to the heart team. Each
member of the heart team (other than the echocar-
diographer) should meet and examine the patient,
after which appropriate decisions regarding clinical
trial eligibility and surgical risk should be reached by
TABLE 8 Risk Assessment in Valvular Heart Disease, Combining Society of Thoracic Surgery Risk Estimates, Frailty, Major Organ System Dysfunction, and
Procedure-Speciﬁc Impediments for Intervention
Low Risk
(ALL Criteria in This Column
Must Be Present)
Intermediate Risk
(At Least 1 Criterion in
This Column Must Be Present)
High Risk
(At Least 1 Criterion in
This Column Must Be Present)
Prohibitive Risk
(Any 1 Criterion in This
Column Must Be Present)
STS PROM* <4% 4%–8% >8% Predicted risk with surgery of death
or major morbidity (all-cause)
Frailty† None 1 index (mild) $2 indexes (moderate to severe) >50% at 1 yr
Major organ system compromise
not to be improved post-
operatively‡
None 1 organ system No more than 2 organ systems $3 organ systems
Procedure-speciﬁc impediment§ None Possible procedure-speciﬁc
impediment
Possible procedure-speciﬁc
impediment
Severe procedure-speciﬁc
impediment
*Use of the STS predicted risk of mortality (PROM) to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 SD of STS average observed/expected
ratio for the procedure in question. †Seven frailty indexes: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting and urinary continence) and independence in
ambulation (no walking aid or assist required for 5-m walk in <6 s). Other scoring systems can be applied to calculate no, mild, or moderate-to-severe frailty. ‡Examples of major organ system compromise:
Cardiac: severe LV systolic or diastolic dysfunction or RV dysfunction, or ﬁxed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1 <50% or DLCO2 <50% of predicted; CNS
dysfunction: dementia, Alzheimer’s disease, Parkinson’s disease, or CVA with persistent physical limitation; GI dysfunction: Crohn’s disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0;
cancer: active malignancy; and liver: any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy. §Examples: tracheostomy present, heavily calciﬁed ascending aorta, chest
malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage. Adapted with permission from Nishimura et al. (1).
CKD ¼ chronic kidney disease; CNS ¼ central nervous system; CVA ¼ cerebrovascular accident (stroke); DLCO2 ¼ diffusion capacity for carbon dioxide; FEV1 ¼ forced expiratory volume in 1 s; GI ¼
gastrointestinal; INR ¼ international normalized ratio; LV ¼ left ventricular; PROM ¼ predicted risk of mortality; RV ¼ right ventricular; STS ¼ Society of Thoracic Surgeons; VKA ¼ vitamin K antagonist.
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298consensus during an in-person meeting of the heart
team.
The local heart team assessment of operative risk
should supersede any single risk score in determining
patient eligibility for surgery. Team decision-making
should integrate clinical risk scores with other
known prognostic variables, including assessment of
frailty. During the consideration of surgical eligibility,
anticipation of individual expected improvement in
symptoms, quality-of-life, and functional status as
well as survival must be considered. Importantly, the
heart team tailors adjustment of the decision-making
process according to local expertise and standards of
care (73). Thus, a patient who is considered to be very
high risk for MV surgery at 1 institution may appro-
priately be considered to be at low or intermediate
surgical risk at a different center. Clinical trials can
accommodate such systematic site-based variability
by stratiﬁcation at the time of randomization on the
basis of risk assessment by objective scores or the
central eligibility committee. Finally, in clinical prac-
tice, patient preferences (shared decision-making)
play an important role, and arbitrary age- and risk-
score–based cutoffs are no longer the dominant
basis for treatment selection. For trials leading to
regulatory approval or indication expansion, the
local heart team determination of surgical risk and
eligibility supersedes other considerations, thus
ensuring enrollment of a clinically appropriate control
group and minimizing crossovers during trial conduct.
FRAILTY. Assessment of patient frailty deserves spe-
cial emphasis. The existence of frailty in an elderly
population is an important parameter for riskstratiﬁcation before major cardiovascular in-
terventions and has demonstrated substantial prog-
nostic capability (74–78). Frailty is a geriatric
syndrome that reﬂects a state of decreased physio-
logical reserve and vulnerability to stressors, and is
characterized by a progressive decline in muscle mass
and strength (74). Multiple frailty criteria and scales
have been proposed (74,79), although the single best
assessment tool remains uncertain. Most experts
agree that the combination of 5-m gait speed, grip
strength, unintentional weight loss, inactivity, and
exhaustion represent the most validated frailty mea-
surements (74). Disability, deﬁned as the inability or
dependency to carry out activities of daily living and/
or managing one’s medications or ﬁnances (instru-
mental activities of daily living), is also an essential
part of the initial geriatric evaluation. Assessment of
baseline and post-procedure cognitive impairment
with clinically established scales such as the Mini-
Mental State Examination, the modiﬁed Telephone
Interview of Cognitive Status, and/or the Clinical De-
mentia Rating Scale should also be considered when
evaluating the utility and cost-effectiveness of inva-
sive procedures among an elderly population (80).
Involvement of experts in neurocognitive dysfunction
(e.g., geriatricians, neurologists) with serial evalua-
tions pre- and post-procedure is essential for mean-
ingful appraisal; however, it should be acknowledged
that evaluation and collection of frailty parameters
can be time consuming and resource intensive.
Further research is required to determine the extent
to which frailty assessments should be a routine part
of MV clinical trials and registries.
J A C C V O L . 6 6 , N O . 3 , 2 0 1 5 Stone et al.
J U L Y 2 1 , 2 0 1 5 : 2 7 8 – 3 0 7 MVARC Part 1: Clinical Trial Design Principles
299PRIMARY AND SECONDARY ENDPOINTS
GENERAL CONSIDERATIONS. Selection of the pri-
mary and major secondary clinical endpoints should
afford an assessment of new technologies that is
meaningful both for regulatory considerations and to
guide clinical use. Such endpoints should give a
robust determination of the beneﬁt-risk balance
afforded to patients receiving the therapy relative to
other therapeutic options. Separate pre-speciﬁed
primary powered safety and effectiveness endpoints
are recommended for most trials of new transcatheter
MV therapies, and the use of a single composite
clinical safety and effectiveness endpoint, especially
when the individual components of safety and efﬁ-
cacy may move in opposite directions, is not
recommended.
Although a single primary endpoint (or set of
endpoints) cannot be pre-determined in this docu-
ment for all possible clinical trials of MR devices and
therapies, general principles may be proposed:
 Major endpoints should address both the safety
and effectiveness of the proposed new device. In
general, separate safety and effectiveness mea-
sures are desirable as coprimary endpoints, and
both safety and effectiveness hypotheses should
typically be met to declare trial/device success.
However, the FDA’s decisions regarding device
regulatory approval are ultimately dependent on a
beneﬁt-risk determination that also takes into ac-
count disease severity, therapeutic options, and
unmet clinical needs for life-threatening and life-
limiting conditions (20).
 The primary effectiveness endpoint should be a
relevant clinical outcome for the population stud-
ied, rather than simply a technical or surrogate
measure of success. However, continued evidence
of device success at the time of primary effective-
ness endpoint assessment should be present to
support the determination that the observed
beneﬁt was due to the device intervention.
 Similarly, meaningful secondary endpoints assess-
ing pathophysiological mechanisms should be
measured that are consistent with and linked to
meaningful clinical outcomes (e.g., reduction in MR
resulting in decreased LA and LV volumes,
improved LVEF, and reduced PAP).
 Additional secondary endpoints may include
functional measures (e.g., exercise performance as
measured by the 6-min walk test or cardiopulmo-
nary exercise testing) (81,82) and patient-reported
quality-of-life outcomes such as the Short-Form
Health Survey-12 or -36 scales, Minnesota Livingwith Heart Failure Questionnaire, Rose dyspnea
scale, the EuroQol instrument, or the Kansas City
Cardiomyopathy Questionnaire (83–87). Efforts to
avoid bias in such determinations, such as patient
and assessor blinding, should be incorporated into
study designs when feasible.
 The primary and secondary safety endpoints
should assess procedural and/or device-related
complications and incorporate any adverse
impact of the intervention on the disease state,
future treatments, and prognosis.
 The primary and secondary endpoints should be
selected such that meeting these endpoints will
demonstrate reasonable assurance of safety and
effectiveness and a favorable beneﬁt-risk proﬁle.
 All endpoints must be well deﬁned such that they
can be subjected to statistical analysis, and clinical
endpoints should rely on the use of independent
adjudication processes, blinded when possible. It is
acknowledged, however, that blinding the central
adjudication committee may be difﬁcult in trials of
MR therapies in which the control and experi-
mental treatments vary so greatly, especially if the
committee must ascribe the extent to which
adverse events are study device-related. This latter
issue may be overcome by adjudicating in 2
discrete steps: 1) whether or not an event (stroke,
myocardial infarction, and so on) occurred; and
then 2) whether or not the event was procedure or
device related.
 Quantitative measures, such as imaging parame-
ters and electrocardiographic changes, should be
assessed by independent core laboratories that are
blinded to treatment assignment when possible.
 Endpoints should be measured at relevant in-
tervals that are appropriate for demonstrating
safety and effectiveness, and the analysis should
incorporate and pre-specify both early and late
endpoints according to previously proposed stan-
dards, including acute intraprocedural events as
deﬁned in part 2 of this document and in earlier
consensus documents (16,17).
 If composite endpoints are necessary to afford
reasonable study size, they should be comprised of
important clinical outcomes related to effective-
ness and/or device safety that may be observed
during the relevant period of observation. The in-
dividual components of the composite endpoint
should share a common pathophysiology or
represent speciﬁc major complications of device
therapy, and should be expected to trend in the
same direction. Major and minor events should be
clearly distinguished to avoid grouping outcomes
of variable clinical signiﬁcance.
TABLE 9 Clinical and Functional Outcome Measures That May Be
Considered for Primary or Secondary Effectiveness Endpoints in
Mitral Regurgitation Trials
Endpoint Primary or Secondary
Clinical measures
Mortality
All-cause Primary or secondary*
Procedure-related Secondary
Cardiac† Primary or secondary*
Heart failure rehospitalization Primary or secondary*
Mitral valve reintervention Secondary*
Need for LVAD or heart transplant Secondary*
Functional measures
6-min walk distance Usually secondary
Cardiopulmonary exercise testing Usually secondary
Validated quality-of-life scales Usually secondary
Change in New York Heart
Association functional class
Secondary
*Or part of a primary composite endpoint. †In general, all-cause mortality is
preferred to cardiac mortality as a primary endpoint. In studies enrolling patients
with numerous noncardiac comorbidities that may result in a high rate of
noncardiac mortality, accurately adjudicating the cause of death may be difﬁcult. If
cardiac mortality is used as a primary endpoint, a neutral effect on noncardiac
mortality with the intervention should be present (accounting for competing
risks).
LVAD ¼ left ventricular assist device.
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300 The statistical analysis of these endpoints should
conform to commonly accepted principles, such as
accounting for competing risks and multiplicity
(see also Statistical Considerations).
Selection of appropriate primary and secondary
endpoints to assess device therapies for MR is espe-
cially challenging, because of a complicated matrix
that includes the underlying risk and comorbidities of
the target population, the speciﬁc pathogenic mech-
anisms of MV dysfunction (e.g., primary vs. second-
ary and ischemic vs. nonischemic etiologies), and
whether options for therapy include MV repair or
replacement surgery, coronary revascularization, and
ventricular resynchronization therapy, in addition to
GDMT. For example, whether mortality is the optimal
stand-alone primary endpoint may depend on the
expected survival rate of the target population with
currently available treatment options. For patient
cohorts in whom short- or intermediate-term mor-
tality is low, other measures, such as outcomes
related to heart failure and functional capacity, may
be more clinically meaningful during the course of a
clinical trial observation if associated with continued
successful device performance.
For studies in which MV surgery is the control
group (e.g., for primary MR in acceptable surgical
candidates), major endpoints must assess the safety
of the new device relative to the complications of
surgery, and demonstrating superiority in safety
with noninferiority in efﬁcacy (within a reasonable
margin reﬂecting therapeutic interchangeability) is a
reasonable goal. Conversely, if the control group is
GDMT with or without coronary revascularization
and/or CRT as appropriate (e.g., for secondary MR in
heart failure), device safety endpoints must be
weighed against superiority measures of clinical ef-
ﬁcacy that would justify the associated procedural
and device-related risks. Whether or not pre-speciﬁed
endpoints are met, FDA approval is based upon the
totality of the data when considered as part of a
thorough beneﬁt-risk determination (20).
PRIMARY ENDPOINTS. Clinically meaningful effec-
tiveness measures to be considered for MR device
therapies are presented in Table 9. All-cause mortality
should be incorporated into the primary efﬁcacy
endpoint (as either a standalone measure or as part of
a composite) if there is a reasonable expectation that
MR reduction might improve survival (e.g., for
primary MR). For clinical trials in which the mor-
tality rate during the time-course of observation is
expected to be high, all-cause mortality as a pre-
speciﬁed and adequately powered standalone
primary efﬁcacy endpoint should strongly beconsidered, as a signiﬁcant improvement in survival
is likely to support a favorable beneﬁt-risk determi-
nation even if other device-related safety issues
emerge. It is also the endpoint least affected by lack
of blinding. Otherwise, all-cause or cardiac mortality
may be part of a carefully constructed primary com-
posite clinical effectiveness endpoint in which the
pathophysiology between the components is shared
and all events are considered clinically important.
In this regard, after all-cause mortality, heart failure-
related outcomes may be the best clinical measure
of effectiveness to use in trials of MR therapies.
As outlined in part 2 of this document, speciﬁc criteria
deﬁning hospitalization or hospitalization equiva-
lents for heart failure may be crafted to allow inde-
pendent adjudication of this event. Hospitalization
for heart failure may serve as a primary standalone
endpoint for conditions in which MR reduction is
anticipated to improve quality-of-life, but may not
necessarily improve survival (e.g., secondary MR in
patients with severe LV dysfunction).
Whether functional measures (e.g., 6-min walk
distance) or quality-of-life indexes are sufﬁciently
clinically important and robust to warrant incorpo-
ration into a primary effectiveness endpoint is
controversial. This consideration is especially rele-
vant in unblinded trials, in which placebo and Haw-
thorne effects as well as assessment bias may make
interpretation of these measures difﬁcult. Proposed
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301measures of functional performance are presented in
Table 9. Such measures might be regarded as having
intermediate value as reviewed by Temple (88),
because they are meaningful to patients and may
eventually result in a favorable effect on survival.
If functional measures or quality-of-life outcomes are
considered as a primary endpoint (either standalone
or as part of a composite endpoint), all possible ef-
forts for blinding should be used (including assess-
ment of the success of the blinding procedures), and
the data should demonstrate continued evidence of
device performance at the time of assessment and
reasonable conﬁdence of lack of harm, including
mortality.
The primary safety endpoint is usually a composite
endpoint speciﬁc to the device and underlying cardiac
condition, and should incorporate the need for un-
planned MV surgery (or reoperation) due to progres-
sive or recurrent MR or device-related complications.
As an example, these principles have been incor-
porated into the design of the COAPT trial, an ongoing
prospective, multicenter randomized trial performed
under an FDA Investigational Device Exemption
in which the MitraClip is being compared to GDMT in
patients with symptomatic severe secondary MR in
whom surgery is not considered appropriate after
local heart team evaluation. The primary effective-
ness endpoint is hospitalization for heart failure
during follow-up (measured by the Andersen-Gill test
to take into account the number of heart failure
hospitalizations), powered to demonstrate superior-
ity of the MitraClip. The primary safety endpoint is
the composite of single leaﬂet device attachments,
device embolization, endocarditis requiring surgery,
core laboratory–conﬁrmed mitral stenosis requiring
surgery, LV assist device implant, heart transplant, or
any device-related complications requiring nonelec-
tive cardiovascular surgery at 12 months, to a pre-
speciﬁed performance goal.
SECONDARY ENDPOINTS. Secondary endpoints should
include the individual components of the primary
endpoint if a composite was used, as well as other
measures of effectiveness that were not a part of the
primary endpoint, including functional, symptom,
and quality-of-life assessments; imaging-related
measures of MR reduction and cardiac structure and
performance; and major and minor safety outcomes
(Table 10). Secondary endpoints of interest that may
be affected by the intervention should be pre-
speciﬁed, but the study may or may not be
adequately powered to demonstrate statistical sig-
niﬁcance for such endpoints even if differences truly
exist. Powered secondary endpoints with pre-
speciﬁed statistical hypotheses are necessary tomake labeling claims for approved medical devices in
the United States. If not powered, secondary end-
points are considered hypothesis generating, even if
pre-speciﬁed. Nonetheless, secondary mechanistic
endpoints may provide valuable guidance for new
device designs or iterations, especially in this early
era of MR device development.
Endpoints should be classiﬁed according to device-
and procedure-relatedness and timing of occurrence
as previously proposed: acute, within 24 h; early,
after 24 h but within 30 days; intermediate, after
30 days but within 1 year; late, between 1 and 5 years;
and very late, after 5 years (17). For secondary
outcome measures (as for the primary endpoints),
safety should be assessed separately from effective-
ness, except possibly for all-cause mortality and
stroke, endpoints that reﬂect both safety and effec-
tiveness of an intervention. Secondary safety end-
points should further evaluate procedural and/or
device-related complications and assess any adverse
effects of the intervention on the disease state, future
treatments, and prognosis (e.g., whether device fail-
ure impedes the likelihood to perform successful
surgical MV repair). If not already identiﬁed as a
standalone primary endpoint, all-cause mortality
should always be pre-speciﬁed as a secondary
endpoint (even if not adequately powered) to
consider whether a new therapy might result in
increased or decreased survival.
Various measures of mechanistic and technical
success are important to include as pre-speciﬁed
secondary outcomes in MR device trials. Although
quantitative reduction in MR is the sine qua non for
treatment effectiveness, and the associated physio-
logical measures (e.g., reduced LA and LV volumes
and PAP, improved LVEF) are consistent with suc-
cessful device performance over time, these surro-
gate endpoints are insufﬁcient to serve as primary
effectiveness endpoints (either standalone or as a
component of a composite measure) because they
may not be associated with clinically meaningful
improvements. Furthermore, small statistically sig-
niﬁcant differences in continuous measures may not
result in clinically measurable beneﬁts. Nevertheless,
a high rate of early technical success, coupled with
continued device functional performance and a
beneﬁcial physiological response over time, should
be present to support the biological plausibility of the
primary clinical effectiveness endpoint. These mea-
sures should, therefore, be evaluated in all MR trials
and reported as secondary efﬁcacy outcomes. MR
severity over time is also an important measure of
durability of the treatment effect and should be
assessed at regular intervals throughout the study
TABLE 11 Timing of Endpoint Assessment (Follow-Up Intervals)
Acute (during procedure or within 24 h)
Procedural (30 days post-procedure or until discharge from
hospital or acute care facility)
90 days
6 months
12 months
Annual (for a minimum of 5 yrs)
TABLE 10 Major Safety, Technical, and Mechanistic Endpoints in
Mitral Regurgitation Trials
Major safety endpoints
Device or procedure-related adverse events (speciﬁc to each device and procedure)
Major bleeding complications (transfusion reported separately)
Major vascular complications
Pulmonary complications (device or procedure-related)
Stroke and other cerebrovascular events (assessed by a stroke neurologist and CT/CMR
imaging; disabling and nondisabling; change in modiﬁed Rankin score)
Myocardial infarction
Acute kidney injury or progression of chronic kidney disease (dialysis reported separately)
New onset atrial ﬁbrillation
Unplanned mitral valve surgery due to device/procedure failure or malfunction
Requirement for valve replacement versus repair
Unplanned cardiac surgery for any cause
Requirement/insertion of an implantable cardiac deﬁbrillator
Requirement/insertion of biventricular pacemaker for cardiac resynchronization therapy
Device failure resulting in the inability to perform successful surgical mitral valve repair
Technical success
Device success (speciﬁc deﬁnition)
Implant rate
Device time and procedure duration
Contrast utilization
Ionizing radiation exposure
Procedural success (speciﬁc deﬁnition)
Mechanistic endpoints*
Imaging measures
Mitral regurgitation severity (integrated assessment; see text and Tables 2 and 3)
Mitral valve area and mean gradient
Left atrial and pulmonary artery pressures
End-systolic dimension and volume
End-diastolic dimension and volume
Left ventricular sphericity
Left ventricular ejection fraction
Left atrial dimension and volume
Right ventricular pressures, dimension, volume, and ejection fraction
BNP and/or NT-pro BNP levels
*Absolute levels and incremental change from baseline.
BNP ¼ B-type natriuretic peptide; CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography;
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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evaluated by a central core laboratory to standardize
reporting and limit potential bias.
ANALYSIS OF PRIMARY AND SECONDARY ENDPOINTS. It
is recommended that primary and secondary end-
points be assessed at the intervals noted in Table 11.
In most MR trials, the primary effectiveness endpoint
should be assessed no sooner than 1 year after
randomization, whereas the primary safety endpoint
may be assessed as soon as 30 days after randomiza-
tion to account for procedural complications (each
taking into account between group differences in
time from randomization to treatment initiation).
Depending on the device, however, follow-up longer
than 30 days may be appropriate for the primary
safety endpoint assessment.The analysis plan should incorporate achievement
of device- and patient-oriented outcomes to assess
overall safety and effectiveness as well as beneﬁt-
risk. As detailed in part 2 of this document, device-
oriented outcomes include technical success with
associated mechanistic outcomes and device- and
procedure-related safety endpoints. Patient-oriented
outcomes include the components of the primary
safety and effectiveness endpoints. A hierarchical
analysis plan should be pre-speciﬁed beginning with
assessment of the primary safety and effectiveness
endpoints followed by analysis of powered major
secondary endpoints assessing functional and mech-
anistic outcomes, with attention to preserving type I
error (alpha) at the 0.05 level. Thereafter, non-
powered secondary endpoints are assessed, as well as
subgroup analyses to examine consistency, although
these exploratory analyses offer lower levels of evi-
dence and are considered hypothesis-generating in
most circumstances.
Finally, it should be noted that over time the level
of evidence required for serial iterations of MR de-
vices or even novel devices will likely change as
experience grows with therapies for treating MR
patients.
ROLE OF THE
CENTRAL ELIGIBILITY COMMITTEE
Even with the use of local heart teams and detailed
protocol inclusion/exclusion criteria, site-based vari-
ability in patient selection for studies of devices
treating MR remains a concern. To enhance inter-
pretability, particularly for regulatory trials of novel
MR devices, it is strongly recommended that each
patient be presented to a central eligibility com-
mittee for evaluation of patient appropriateness for
enrollment. The central eligibility committee serves
multiple important functions (Table 12). The members
of the central eligibility committee for MR trials
should include at a minimum a moderator, a heart
failure specialist, and an experienced MV surgeon.
Each patient should be presented to the committee by
TABLE 12 The Central Eligibility Committee
Purpose To ensure that key eligibility criteria are met before enrollment into a clinical
trial. For example (depending on the trial):
 to ensure the patient is appropriately symptomatic
 to ensure the appropriate severity of MR, left ventricular function,
and chamber size are present*
 to ensure the patient is treated and is adherent with optimal guideline-
directed medical therapy for heart failure, including maximally
tolerated doses of each indicated class of medication
 to ensure the patient does not require additional (non-mitral valve)
cardiac surgery, coronary revascularization or ICD/CRT therapy
Composition Depends on the speciﬁc study, but in general consists of:
 moderator (voting or nonvoting; may also serve 1 of the following
roles)
 heart failure specialist (voting)
 high-volume MV cardiac surgeon (voting)
  MV cardiologist (voting)
  interventional cardiologist experienced in MV procedures (voting)
Sponsor may be present (nonvoting)
Presenting
physicians
Members of the local heart team, including at a minimum (depending on
the trial):
 local principal investigator
 heart failure specialist and/or valve cardiologist
 MV cardiac surgeon
Format Web-based telephone calls at which original source documents are reviewed
(clinical data, medications, laboratory results, echocardiograms,
electrocardiograms, and so on). Detailed notes are taken. After patient
review, a vote is held and recorded.
Outcome Patients will be approved, denied, or deferred
*Ideally determined by echocardiographic core laboratory review of the qualifying imaging studies before the
central eligibility committee meeting.
CRT ¼ cardiac resynchronization therapy; ICD ¼ implantable cardioverter-deﬁbrillator; other abbreviations as
in Table 2.
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speciﬁc requirements for the trial, a cardiologist with
expertise in valvular heart disease, a heart failure
specialist, and/or an MV cardiac surgeon. The MV
surgeon plays a central role in all MR randomized tri-
als, whether the control arm is surgery (as for most
trials of primary MR) or GDMT (as for most trials of
secondary MR). Before the committee meeting, a
central echocardiographic core laboratory should have
reviewed the qualifying TTE (TEE) to ensure that the
MRmeets severity criteria and, depending on the trial,
to conﬁrm that other eligibility criteria are met (e.g.,
LV volumes, LVEF, MR etiology and anatomy, absence
of mitral stenosis, and so on). Depending on the spe-
ciﬁc device, the central echocardiographic core labo-
ratory may also be asked to determine whether
appropriate anatomy is present for device eligibility.
Although implementation of a central eligibility com-
mittee and pre-review by a central echocardiographic
core laboratory entail extra time and cost, ensuring
that only appropriate patients are enrolled in the
clinical trial will substantially increase the power of
the study and the likelihood of success.
An important distinctionmust bemade between the
roles of the local heart team and the central eligibility
committee. Both multidisciplinary groups possess
expertise to evaluate surgical risk and clinical trial
eligibility. However, the thresholds at which MV sur-
gery might be considered reasonable vary from center
to center and surgeon to surgeon, depending on local
experiences and volume considerations. The subtle-
ties of the patient’s clinical condition (and surgical
risk) are also best assessed by those able to speak to
and examine the patient. Thus, the local heart team
determines the relative surgical risk and operability of
a patient, rather than the central eligibility committee.
The MV surgeon (and others) on the central eligibility
committeemay, however, query the local surgeon as to
his/her criteria for operability to ensure, for example,
that crossover to surgery will not be considered should
the patient be randomized to a nonsurgical therapy
(unless permitted by the protocol).
STATISTICAL CONSIDERATIONS
GENERAL CLINICAL TRIAL DESIGN ISSUES. Most
clinical studies of new devices addressing MR will be
randomized trials. Crossovers should be discour-
aged, and in all cases not permitted until the primary
endpoint has been reached. Contemporary adaptive
designs that expose the fewest patients to an inferior
therapy may be applicable to randomized trials with
short-term primary endpoints, multiple trial arms,
and the ability to switch to a long-term endpoint(89). Single-arm trials using historical comparators
may be appropriate when the condition to be
examined is infrequent or no adequate comparator
exists. Single-arm trials may also be appropriate
when a body of published data exists that is sufﬁ-
cient for construction and justiﬁcation of appropriate
performance goals or following development of
objective performance criteria. As the ﬁeld matures,
single-arm studies may become appropriate for
serial device iterations or studies of similar device
designs.
TRIAL ENDPOINTS AND ANALYSIS. Endpoints fall
into 3 categories: 1) early post-procedure events and
measures (e.g., death, stroke, valvular regurgitation);
2) time-related events (e.g., death, stroke); and 3)
periodically sampled longitudinal data (e.g., valvular
regurgitation, chamber dimensions, NYHA functional
class). Early events are compared as odds ratios, early
measurements are compared as differences, time-
related events are compared as actuarial curves and
hazard ratios, and longitudinal data are compared
as time-related differences in ensemble averages.
Although each trial must carefully evaluate and adopt
the statistical methodology most appropriate for its
goals, the following general principles may be useful
to consider.
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304Nonfata l t ime-re lated events . Nonfatal events
can repeat (e.g., stroke, rehospitalization). All occur-
rences should be analyzed, not just time to ﬁrst
occurrence, using the Nelson (90), Andersen-Gill
(91), or other estimators (92). These methods make
different assumptions with respect to the indepen-
dence of events, hazard function after each occur-
rence, and informativeness of death and other
competing risks (93).
Weighted events . Although generally not done,
consideration may be given to weighing nonfatal
events (e.g., by applying the National Institutes of
Health stroke scale and considering the duration
and cost of rehospitalization), which may be further
analyzed as cumulative functions, a common indus-
trial method when considering costs (90,94,95).
Longi tud ina l data . Longitudinal data reﬂect an
endpoint’s state at time of assessment; they are not
time-to-event data (96). Examples are drug use
(binary), functional status (ordinal), and EROA
(continuous). Such endpoints should be analyzed by
longitudinal repeated measures methods (96).
Ensemble averages across time are subject to infor-
mative censoring from events with which they are
associated.
Compos i te endpoints . The use of composite end-
points to reduce sample size is a practical conven-
tion, but if not carefully constructed, may lead
to difﬁculties in interpretation (97). Typically, each
component is equally weighted, although the
hazard function for each may be different (e.g., the
Andersen-Gill method assumes proportional hazards
[91]). However, clinical hierarchy or patient prefer-
ence for each component may differ. If the compo-
nents can be hierarchically arrayed, tree-structured
gatekeeping tests (98) or pair-wise winner-loser
strategies (99) may be used. Family-wise tests of in-
dividual components emphasize consistent direction
of effect (100).
The most controversial composite endpoints com-
bine disparate component categories. Several groups,such as Finkelstein and Schoenfeld (101), have
developed methods that combine time-to-event
components with periodic longitudinal assessments.
Others have extended this to continuous longitudinal
data combined with weighted time-to-event data
(102). On the horizon are joint models that account
simultaneously for different intensity functions of
each event and longitudinal components and their
interrelations (103).
CONCLUSIONS
In contrast to calciﬁc aortic stenosis, a relatively
simple disease with limited etiologies and a straight-
forward pathophysiology, MR is a more complicated
entity, due to the greater complexity of the MV
structure and the numerous lesions and mechanisms
that may lead to its failure. Central to the under-
standing of MR is recognizing that MR is indeed 2
disorders: 1 of the valve apparatus itself and 1 of the
LV (or LA), which secondarily disrupts normal MV
function. Continuing the analogy, developing effec-
tive therapies (and surgical approaches) for MR and
demonstrating their safety and effectiveness in clin-
ical trials is much more challenging than for aortic
stenosis, and requires the intimate collaboration be-
tween physician-scientists across numerous disci-
plines, clinical trialists, statisticians, and industry
and regulatory authorities. Although each device trial
will entail its own nuanced considerations, adopting
the principles espoused in this document as a tem-
plate for clinical investigation of mitral therapeutics
should allow sponsors and investigators to avoid the
most common errors that can render interpretation of
their ﬁndings problematic.
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